Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V and minimal evidence of brain penetration

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

File size: 1.60 MB
Created: October 2021
Updated: October 2024
Hits: 37
Download Preview
Scroll to Top
Scroll to Top